NEW YORK (GenomeWeb News) – Interleukin Genetics said after the close of the market on Tuesday that its revenues for the second quarter were essentially flat compared to the year-ago period.

The Waltham, Mass.-based genetic test developer said that during the three months ended June 30, it brought in revenues of $799,435, compared to $796,865 for Q2 a year ago. Genetic testing service revenue dipped slightly to $777,549 from $779,116 while other revenues increased to $21,886 from $17,749.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.